Bear bile powder inhibits angiogenesis in vivo and in vitro

Jin-yan Zhao; Wei Lin; Qun-chuan Zhuang; Xiao-yong Zhong; Jun Peng; Zhen-feng Hong

doi:10.1007/s11655-015-2062-0

Your Location：

Home >

Browse articles >

Bear bile powder inhibits angiogenesis in vivo and in vitro

Updated：2021-08-27

- Bear bile powder inhibits angiogenesis in vivo and in vitro
- Chinese Journal of Integrative Medicine Vol. 21, Issue 5, Pages: 369-375(2015)
- Affiliations：
  
  1. Fujian Academy of Integrative Medicine,Fuzhou,China
  2. Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine,Fuzhou,China
- Author bio：
- Funds：
  
  Supported by Important Science and Technology Specific Projects of Fujian Province (No. 2010YZ0001-1 and 2010Y2004), and the Developmental Fund of Chen Ke-ji Integrative Medicine (No. CKJ 2010019)
- DOI：10.1007/s11655-015-2062-0
  CLC：
- Published：2015，
  
  Published Online：17 March 2015，
Scan for full text
Zhao, Jy., Lin, W., Zhuang, Qc. et al. Bear bile powder inhibits angiogenesis in vivo and in vitro, ., Chin. J. Integr. Med. 21, 369–375 (2015). https://doi.org/10.1007/s11655-015-2062-0

Jin-yan Zhao, Wei Lin, Qun-chuan Zhuang, et al. Bear bile powder inhibits angiogenesis in vivo and in vitro. [J]. Chinese Journal of Integrative Medicine 21(5):369-375(2015)
Zhao, Jy., Lin, W., Zhuang, Qc. et al. Bear bile powder inhibits angiogenesis in vivo and in vitro, ., Chin. J. Integr. Med. 21, 369–375 (2015). https://doi.org/10.1007/s11655-015-2062-0 DOI：

Jin-yan Zhao, Wei Lin, Qun-chuan Zhuang, et al. Bear bile powder inhibits angiogenesis in vivo and in vitro. [J]. Chinese Journal of Integrative Medicine 21(5):369-375(2015) DOI： 10.1007/s11655-015-2062-0.

摘要

To evaluate the effect of bear bile powder (BBP) on angiogenesis

and investigate the underlying molecular mechanisms. A chick embryo chorioallantoic membrane (CAM) assay was used to evaluate the angiogensis in vivo. Human umbilical vein endothelial cells (HUVECs) were treated with 0

0.25

0.5

0.75

and 1.0 mg/mL of BBP for 24

48 and 72 h

respectively. The 3-(4

5-dimethylthiazol-2-yl)-2

5-diphenyltetrazolium bromide assay was performed to determine the viability of HUVECs. Cell cycle progression of HUVECs was examined by fluorescence-activated cell sorting (FACS) analysis with propidium iodide staining. HUVEC migration was determined by wound healing method. An ECMatrix gel system was used to evaluate the tube formation of HUVECs. The mRNA and protein expression of vascular endothelial growth factor (VEGF)-A in both HUVECs and HepG2 human cells were examined by reverse transcription-polymerase chain reaction and enzyme linked immunosorbent assay

respectively. Compared with the untreated group

BBP inhibited angiogenesis in vivo in the CAM model (P< 0.01). In addition

treatment with 0.25–1 mg/mL of BBP for 24

or 72 h respectively reduced cell viability by 14%–27%

29%–69% and 33%–91%

compared with the untreated control cells (P< 0.01). Additionally

BBP inhibited the proliferation of HUVECs via blocking the cell cycle G to S progression

compared with the S phase of untreated cells 48.05%± 5.00%

0.25–0.75 mg/mL BBP reduced S phase to 40.38%± 5.30%

36.54± 4.50% and 32.13± 3.50%

respectively (Pglt; 0.05). Moreover

BBP inhibited the migration and tube formation of HUVECs

compared with the tube length of untreated cells 100%± 12%

0.25–0.75 mg/mL BBP reduced the tube length to 62%± 9%

43%± 5% and 17%± 3%

respectively (p< 0.01). Furthermore

BBP treatment down-regulated the mRNA and protein expression levels of VEGF-A in both HepG2 cells and HUVECs. BBP could inhibit the angiogenesis by reducing VEGF-A expression

which may

in part

explain its anti-tumor activity.

Abstract

To evaluate the effect of bear bile powder (BBP) on angiogenesis

0.25

0.5

0.75

and 1.0 mg/mL of BBP for 24

48 and 72 h

respectively. The 3-(4

5-dimethylthiazol-2-yl)-2

respectively. Compared with the untreated group

BBP inhibited angiogenesis in vivo in the CAM model (P< 0.01). In addition

treatment with 0.25–1 mg/mL of BBP for 24

or 72 h respectively reduced cell viability by 14%–27%

29%–69% and 33%–91%

compared with the untreated control cells (P< 0.01). Additionally

BBP inhibited the proliferation of HUVECs via blocking the cell cycle G to S progression

compared with the S phase of untreated cells 48.05%± 5.00%

0.25–0.75 mg/mL BBP reduced S phase to 40.38%± 5.30%

36.54± 4.50% and 32.13± 3.50%

respectively (Pglt; 0.05). Moreover

BBP inhibited the migration and tube formation of HUVECs

compared with the tube length of untreated cells 100%± 12%

0.25–0.75 mg/mL BBP reduced the tube length to 62%± 9%

43%± 5% and 17%± 3%

respectively (p< 0.01). Furthermore

BBP treatment down-regulated the mRNA and protein expression levels of VEGF-A in both HepG2 cells and HUVECs. BBP could inhibit the angiogenesis by reducing VEGF-A expression

which may

in part

explain its anti-tumor activity.

关键词

bear bile powderhepatocellular carcinomatumor angiogenesishuman umbilical vein endothelial cellsChinese Medicine

Keywords

bear bile powderhepatocellular carcinomatumor angiogenesishuman umbilical vein endothelial cellsChinese Medicine

references

Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300–4308.

Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002;963:13–20.

Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143–154.

Abou-Alfa GK, Huitzil-Melendez FD, O’Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2:64–70.

Boose G, Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Letters 2000;116:7–16.

Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006;1766:184–196.

Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767–776.

Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215–234.

Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. EMBO Reports 2009;10:194–200.

Tang W, Eisenbrand G, eds. Chinese drugs of plant origin: chemistry, pharmacology and use in traditional and modern medicine. Berlin: Springer;1992:11.

Zhao J, Jiang P, Zhang WD. Molecular networks for the study of TCM pharmacology. Brief Bioinform 2009;11:417–430.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27–31.

Folkman J. Angiogenesis. Annu Rev Med 2006;57:1–18.

Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222–243.

Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986;46:467–473.

Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039–3051.

Wang LY, Gao X, Tong ZL, Wang XG. Summary on pharmacological action and clinical study of the chemical composition of bear bile. Chin J Inf Tradit Chin Med (Chin) 2005;22:30–33.

Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, et al. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed 2009;12:5–12.

Yu SZ. Pharmacological effects and clinical application of Bear bile. Lishizhen Med Mater Med Res (Chin) 2007;18:707–708.

Xu HB, Sun X, Wen FC, Zhou JH, Li SL, Ding T, et al. Asurvey and prospect of the research of bear bile. Chin J Inf Tradit Chin Med (Chin) 1998;5:18–20.

Jin Y, Wen YS, Cui YZ, Jin RH. Effects of bears’ bile on the expression of tumor cell p53 protein. Chin J Integr Tradit West Med (Chin) 2006;26:86–88.

Sun TM, Liang W, Zhang QM, Jin Y, Hu XH, Zheng XC. Anti-tumor effects of bear bile. Liaoning J Tradit Chin Med (Chin) 2003;30:66.

Zhao JY, Chen ZH, Lin W, Zhong XY, Chen XZ, Peng J, et al. Bear bile powder induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway. Chin J Integr Med 2014;20:123–129.

Gao XM, ed. Chinese materia medica. Bejing: China Chinese Medicine Publisher;2002:160–161.

Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.

Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996;6:454–456.

Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol1996;3:881–885.

Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10–14.

Jain RK. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2002;29:3–9.

Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–674.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.

Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572–577.

Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858–863.

Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, et al. Predictive value of vascular endothelial growth factor in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379–1384.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway

Effects of Pien Tze Huang (片仔癀) on angiogenesis in vivo and in vitro

Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial

Effects on the tumor specific growth factor and tumor necrosis factor α in rats’ precancerous lesion of primary hepatocellular carcinoma by direct moxibustion at Ganshu (BL 18) acupoint

Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma

Related Author

No data

Related Institution

Fujian Guizhentang Pharmaceutical Co., Ltd.

Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine

Postdoctor Workstation, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰